A Phase 1 interventional study of Aripiprazole 10 MG and Placebo in Stuttering, Adult, sponsored by University of California, San Francisco. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by University of California, San Francisco · Phase 1, Interventional, and Basic science
This study is being done to understand the effect of aripiprazole on adults who stutter. Stuttering is a disorder that affects speech fluency. This study aims to understand sensorimotor pathways of stuttering and possible interventions.
Stuttering is a disorder of speech fluency that affects 3.5 million people in the USA alone. The goal of this project is to assess whether fluency ehnancement with auditory feedback manipulations or with pharmacological agents that regulate dopamine uptake improve the sensorimotor functions of speech feedback prediction and processing in stuttering.
This study may lay the foundation for stuttering treatments that combine dopamine regulators and behavioral treatments. Aripiprazole is an FDA-approved anti-psychotic typically used for treatment of schizophrenia or acute manic episodes. A typical dose is 10-15 mg per day, given daily for treatment. In this study, one 10 mg dose will be given. The usage in this study is purely investigational (experimental) and not FDA approved.
74 studies on the registry are indexed under Stuttering; 23 are open to participants now.
This study's planned enrollment of 25 is below the median of 44 across 57 interventional studies indexed under Stuttering.
Browse Stuttering studies →University of California, San Francisco is the lead sponsor of 2,169 studies on the registry; 372 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 202 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Single dose of aripiprazole, 10mg administered orally. Participant and administrator will be blinded.
Drug: Aripiprazole 10 MG
A single placebo dose will be administered.
Drug: Placebo
The effects of aripiprazole on stuttering and various behavioral and neural outcomes will be studied compared to placebo.
Placebo will be compared against aripiprazole for effect on stuttering and various behavioral and neural markers.
Pre-speech auditory modulation
Pre-speech auditory modulation (PSAM) is a measure of auditory cortical activity (as collect via magnetoencephalography) in response to a speaking and and matching silent reading task.
Time frame: 3-4 hours after intervention dose is delivered
Speaking Induced Suppression (SIS)
SIS is a phenomenon measured through magnetoencephalography that is a marker of auditory cortical response to self-produced speech compared with playback of the same speech.
Time frame: 3-4 hours after intervention
Centering
This is a speech behavior associated with SIS involving a reduction of speech variability from speech onset to mid-utterances. This is derived from auditory recordings occurring during magnetoencephalography collection.
Time frame: 3-4 hours after intervention
Feedback alterations
This is a measure of fluency enhancement by altered speech feedback (manipulated by methods such as masking noise, frequency shifted feedback,. etc.) This is measured through audio recordings and brain activation patterns during magnetoencephalography.
Time frame: 3-4 hours after intervention
Plan to share: Yes — Audio and video recordings to verify presence of stuttering will be shared with investigators at University of Washington. De-identified MEG data or results may also be shared with University of Washingotn.
Supporting information: Study protocol, Statistical analysis plan
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
University of California, San Francisco →